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parameters that can be combined to produce suitable measures of cost (c) and clinical 
benefits (e) associated with an intervention. Within the Bayesian framework (which is 
the natural environment for BCEA), this amounts to estimating a posterior distribu-
tion for the pair (e, c). Health economic evaluations then proceed by computing some 
relevant summaries of the resulting decision process: is the innovative intervention t1 
more “cost-effective” than the standard intervention t0?. Methods: BCEA provides a 
set of functions that can be used to produce a standardised analysis, by synthesising 
the decision process given the current evidence and uncertainty, as well as producing 
several indicators that can be used to perform Probabilistic Sensitivity Analysis (PSA) 
to parameter and model structure uncertainty. These include the Cost-Effectiveness 
Acceptability Curve and the analysis of the Expected Value of Information, which can 
be used to prioritize research. Results: BCEA uses as inputs vectors of simulations 
from the distributions of the average costs and benefits. This naturally fits the Bayesian 
framework, but a frequentist analysis can also be carried out by using tools such as 
the bootstrap. There is scope for linking R and programs such as Excel to facilitate a 
comprehensive health economic analysis, including extensive PSA. ConClusions: 
In this talk, I will present the main feature of BCEA and its applicability to the wider 
context of health economic evaluation and cost-effectiveness analysis.
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objeCtives: Budget impact models (BIMs) which demonstrate the economic impact 
of introducing or increasing the use of specific treatments are routinely used to assist 
the NHS with financial planning. A core component of any BIM is the estimation 
of the eligible patient population. The objective of this study was to identify an 
appropriate methodology for estimating the size of the stage IIIb/IV EGFR M+ non-
small cell lung cancer (NSCLC) patient population eligible for first-line treatment 
with a tyrosine kinase inhibitor such as afatinib (GIOTRIF®). Methods: A review 
of the approach taken by NICE in the costing statements of all treatment options 
for patients with advanced (stage IIIb) or metastatic (stage IV) EGFR M+ NSCLC was 
conducted. The costing statements of tyrosine kinase inhibitors afatinib, erlotinib 
and gefitinib were reviewed, as was the costing statement for the chemotherapy 
agent pemetrexed. Results: Based on the reviewed approaches, the calculation can 
be broken down into six discrete steps from the estimation of the general popula-
tion to the target population: (1) Incidence of lung cancer; (2) Proportion of NSCLC; 
(3) Proportion with stage IIIb/IV NSCLC; (4) Proportion who receive first-line chemo-
therapy; (5) Proportion with EGFR mutation status; and (6) Proportion who are EGFR 
M+. A detailed breakdown of the methods used to calculate the patient population 
eligible for treatment with afatinib was not available in the respective NICE costing 
statement; however the eligible population estimated by NICE validates that this 
approach is reasonable. ConClusions: The methodology employed by NICE to 
estimate the proportion of stage IIIb/IV EGFR M+ NSCLC patients was broadly con-
sistent across all costing statements considered. Is it reasonable to assume that this 
approach, used to estimate the population of stage IIIb/IV EGFR M+ NSCLC patients 
in England and Wales is also applicable in Scotland and Ireland.
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objeCtives: There is a growing need to consider heterogeneity in cost-effectiveness 
analyses (CEA). To capture heterogeneity, subgroups analyses have been performed 
using various socio-demographic and clinical variables. However, the results of these 
subgroups CEA can be considered inequitable. Consequently, there is need to find new 
subgroups that can be used for decision-making. Methods: We explore whether 
subgroups defined by care-seeking behaviors are good candidates for CEA subgroup 
analysis. Care-seekers are defined as patients who received both an early diagnosis 
and an early treatment. We use data from the PLASA study, a French randomized 
controlled trial designed to reduce the rate of functional decline in Alzheimer’s 
disease: 1,131 patients were randomized in an intervention group and in a control 
group and were followed during a 2-year period. We use a sample selection model to 
explore whether the unobserved heterogeneity associated with the early diagnosis 
decision is correlated with the unobserved heterogeneity associated with the early 
treatment decision. We use a fixed-effect model to explore whether the rate of func-
tional decline was lower within the care-seekers subgroup. Results: Our theoreti-
cally grounded selection model shows that the care-seeking behavior is associated 
with unobserved preferences, motivating the need to run subgroup analyses within 
a subgroup of care-seekers. Our fixed-effect model results show that on average, 
the clinical intervention was not effective. However, the intervention was effective 
within the subgroup of care-seekers. Care-seekers who received the intervention did 
not face a significant decline in their functional status over the 2-year study period. 
On the contrary, care-seekers in the control group lost on average 9 points of ADCS-
ADL per year (p< 0.01). ConClusions: Stratifying CEAs by care-seekers subgroups 
seems relevant. Our analyses can be easily implemented by adding three questions 
in the clinical protocol.
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objeCtives: To identify groups of countries with similar health prefer-
ences. Methods: Cluster analyses were performed for the 242 states of the gen-
eral population EQ-5D valuations for 13 published studies based on Time Trade 
Off; and for 10 studies based on the Visual Analogue Scale. The perfect health state 
was not included. Cluster and their optimal number were identified by means of 
the Ward algorithm with the Euclidean measure and the hierarchical clustering 
technique. The identified clusters in each case are compared in order to find out 
whether they coincide. Results: 3 clusters were identified for TTO: 1) Germany, 
Argentina, Poland, The Netherlands, Denmark; 2) Japan, South Korea, USA, Hispanic 
USA, Zimbabwe; 3) Spain, Chile, UK. 4 clusters were identified for VAS: 1) Belgium, 
New Zealand, Germany; 2) Europe, UK, Spain; 3) Denmark, Slovenia; 4) Finland, 
Argentina. Countries are not in the same clusters for the two methodologies. Only 
the UK and Spain belong in the same groups in both cases. ConClusions: Health-
state valuations tend to be clustered in a few groups of countries but the groups 
differ according to the methodology. This suggests that Visual Analogue Scale results 
may not be a good approximation to Time Trade Off.
PRM39
iMtA PRoductivity cost QuestionnAiRe (iPcQ)
Bouwmans C.1, Krol M.2, Brouwer W.2, Severens J.L.1, Koopmanschap M.A.2, Hakkaart L.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, 
The Netherlands
objeCtives: Productivity costs often reflect a large part of the total cost in eco-
nomic evaluations adopting a societal perspective. Currently, no consensus exists 
on how productivity losses are best measured. We aimed to develop a standardized 
instrument for measuring productivity losses to enhance the comparability and gen-
eralizability of the outcomes of economic evaluations. Methods: A focus group 
of well-experienced researchers in the field of measuring and valuing productivity 
losses for use in economic evaluations assessed the instruments’ main quality criteria 
including: building on pre-knowledge and evidence on items’ reliability and valid-
ity, inclusion of all relevant domains of productivity losses, allowing for quantifying 
productivity losses suitable for self-report. A feasibility study was performed to check 
on consistency and intelligibility of the questionnaire and applicability for different 
valuation methods. Results: The focus group identified three separate aspects of 
productivity losses leading to three modules in the iPCQ. Questions for measuring 
absenteeism and presenteeism are evidence- based originating from the Short-Form 
Health & Labour Questionnaire and PRODISQ. As evidence regarding measurement of 
losses of unpaid work is lacking, the questions of this module were developed during 
brainstorm sessions, based on similar questions on paid work. To enhance the instru-
ments’ feasibility and responsiveness the draft version was translated into language 
level 1 by an agency specialized in language and clear writing. The feasibility study 
included 195 respondents aged > 18 years. Five percent identified problems while 
filling in the iPCQ, including the questionnaire’s instructions and routing (n= 8) and 
wording (n= 2). ConClusions: The iPCQ is based on previously available instruments 
and satisfies the current scientific state of play in productivity cost measurement 
and valuation. The instrument is understandable for the vast majority of the general 
public including low-educated people. To enhance the applicability of the iPCQ for 
national and international studies a translation in English is performed.
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objeCtives: There is a growing need for early evaluation of innovative technologies 
to prevent ineffective and expensive technologies to be widely diffused in health 
care. The headroom method was introduced for early determination of the potential 
value of new technologies. In this study we explore the feasibility and usefulness of 
the headroom method in the early assessment of diagnostic technologies with no 
immediate treatment implications. Methods: We applied the headroom method 
to the implementation of whole exome sequencing (WES) into the current diagnostic 
trajectory of complex pediatric neurology. We determined the room for improvement 
regarding health-related quality of life (HRQoL), diagnostic yield and the duration of 
the current diagnostic trajectory. Results: The headroom in a certain diagnostic 
trajectory can be calculated after the so-called effectiveness gap is established and 
monetised. The preferred measure for the effectiveness gap is HRQoL expressed in 
quality-adjusted life years (QALYs). Since the direct product of diagnostics is informa-
tion, and not improved health, no impact on HRQoL is expected. Other measures, such 
as diagnostic yield, can also be used to calculate the effectiveness gap. Unlike QALYs, 
these appeared difficult to monetise, however. Despite this difficulty, effectiveness gap 
calculation using these effect measures is very informative on the room for improve-
ment in current clinical practice. In combination with foreseeable downstream costs 
and savings due to a new technology it gives an idea of the potential societal value of 
this technology. ConClusions: Despite some methodological challenges, the head-
room method proved to be potentially useful in early health economic evaluation of 
diagnostic technologies with no immediate treatment implications.
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objeCtives: BCEA is a R library specifically designed to post-process the result of a 
health economic model. Typically, this consists in the estimation of a set of relevant 
